Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB‐positive acute lymphoblastic leukemia patients: A retrospective multicenter study

PDGFRB公司 医学 内科学 回顾性队列研究 累积发病率 单变量分析 儿科 胃肠病学 多元分析 队列 生物化学 基因 化学
作者
Xiaoyan Zhang,Yaqin Wang,Xin Tian,Lirong Sun,Hua Jiang,Jinhua Chu,Fen Zhou,Shuhong Shen,Shaoyan Hu,Yongjun Fang,Changcheng Lai,Xiuli Ju,Xiaoxiao Xu,Xiaowen Zhai,Hui Jiang,Minghua Yang,Alex Wing Kwan Leung,Ning Xue,Yingchi Zhang,Jun J.J. Yang
出处
期刊:Cancer [Wiley]
卷期号:130 (22): 3902-3912 被引量:7
标识
DOI:10.1002/cncr.35481
摘要

BACKGROUND: PDGFRB fusions in acute lymphoblastic leukemia (ALL) is rare. The authors identified 28 pediatric PDGFRB-positive ALL. They analyzed the features, outcomes, and prognostic factors of this disease. METHODS: This multicenter, retrospective study included 6457 pediatric patients with newly diagnosed PDGFRB fusion ALL according to the CCCG-ALL-2015 and CCCG-ALL-2020 protocols from April 2015 to April 2022 in 20 hospitals in China. Of these patients, 3451 were screened for PDGFRB fusions. RESULTS: /L at baseline. Only one patient had eosinophilia. Three patients had an IKZF1 deletion, three had chromosome 5q31-33 abnormalities, and one suffered from a complex karyotype. The 3-year event-free survival (EFS), overall survival (OS), and cumulative incidence of relapse (CIR) were 33.1%, 65.5%, and 32.1%, respectively, with a median follow-up of 25.5 months. Twenty patients were treated with chemotherapy plus tyrosine-kinase inhibitors (TKIs) and eight were treated without TKI. Complete remission (CR) rates of them were 90.0% and 63.6%, respectively, but no differences in EFS, OS, or CIR. Univariate analyses showed patients with IKZF1 deletion or measurable residual disease (MRD) ≥0.01% after induction had inferior outcomes (p < .05). CONCLUSIONS: Pediatric PDGFRB-positive ALL has a poor outcome associated with high-risk features. Chemotherapy plus TKIs can improve the CR rate, providing an opportunity for lower MRD levels and transplantation. MRD ≥0.01% was a powerful adverse prognostic factor, and stratified treatment based on MRD may improve survival for these patients. PLAIN LANGUAGE SUMMARY: Pediatric acute lymphoblastic leukemia patients with PDGFRB fusions are associated with high-risk clinical features such as older age, high white blood cell count at diagnosis, high measurable residual disease after induction therapy, and increased risk of leukemia relapse. Chemotherapy plus tyrosine-kinase inhibitors can improve the complete remission rate and provide an opportunity for lower measurable residual disease (MRD) levels and transplantation for pediatric PDGFRB-positive acute lymphoblastic leukemia (ALL) patients. The MRD level was also a powerful prognostic factor for pediatric PDGFRB-positive ALL patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
banana的应助被欧阳万仇采纳,获得10
刚刚
郑睿涛发布了新的文献求助10
1秒前
零负一的应助被ZPC采纳,获得30
1秒前
贪玩果汁完成签到,获得积分10
2秒前
2秒前
英俊夜云完成签到,获得积分10
3秒前
3秒前
共享精神的应助被叫你吃布丁采纳,获得10
3秒前
科研小李发布了新的文献求助10
4秒前
木子发布了新的文献求助10
6秒前
6秒前
英姑的应助被lll采纳,获得10
6秒前
6秒前
冲冲发布了新的文献求助10
6秒前
zsda发布了新的文献求助10
7秒前
不暗完成签到 ,获得积分10
7秒前
小二郎的应助被uilyang采纳,获得10
7秒前
王焕玉完成签到,获得积分10
7秒前
从未停步发布了新的文献求助10
7秒前
7秒前
tourist585发布了新的文献求助10
8秒前
9秒前
9秒前
10秒前
10秒前
共享精神的应助被dzy采纳,获得10
11秒前
11秒前
豆芽菜发布了新的文献求助10
11秒前
董兴宇完成签到,获得积分10
11秒前
花花完成签到,获得积分20
12秒前
12秒前
12秒前
12秒前
TaoJ的应助被cccxy采纳,获得10
13秒前
payload发布了新的文献求助10
13秒前
13秒前
武宁完成签到,获得积分10
13秒前
章鱼发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183730
求助须知:如何正确求助?哪些是违规求助? 9572975
关于积分的说明 21828453
捐赠科研通 7780887
什么是DOI,文献DOI怎么找? 3434086
关于科研通互助平台的介绍 2558276
邀请新用户注册赠送积分活动 2480557